Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 200

1.

Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.

Pinazza M, Ghisi M, Minuzzo S, Agnusdei V, Fossati G, Ciminale V, Pezzè L, Ciribilli Y, Pilotto G, Venturoli C, Amadori A, Indraccolo S.

Oncogene. 2018 Apr 12. doi: 10.1038/s41388-018-0234-z. [Epub ahead of print]

PMID:
29643474
2.

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

Savino AM, Sarno J, Trentin L, Vieri M, Fazio G, Bardini M, Bugarin C, Fossati G, Davis KL, Gaipa G, Izraeli S, Meyer LH, Nolan GP, Biondi A, Te Kronnie G, Palmi C, Cazzaniga G.

Leukemia. 2017 Nov;31(11):2365-2375. doi: 10.1038/leu.2017.93. Epub 2017 Mar 23.

PMID:
28331226
3.

Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells.

Angeletti F, Fossati G, Pattarozzi A, Würth R, Solari A, Daga A, Masiello I, Barbieri F, Florio T, Comincini S.

Front Mol Neurosci. 2016 Oct 27;9:107. eCollection 2016.

4.

Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.

Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, García S, Malvar Fernandez B, McKinsey TA, Tak PP, Fossati G, Mascagni P, Baeten DL, Reedquist KA.

Ann Rheum Dis. 2017 Jan;76(1):277-285. doi: 10.1136/annrheumdis-2015-209064. Epub 2016 Jul 25.

5.

SNAP-25, a Known Presynaptic Protein with Emerging Postsynaptic Functions.

Antonucci F, Corradini I, Fossati G, Tomasoni R, Menna E, Matteoli M.

Front Synaptic Neurosci. 2016 Mar 24;8:7. doi: 10.3389/fnsyn.2016.00007. eCollection 2016. Review.

6.

An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.

Pinazza M, Borga C, Agnusdei V, Minuzzo S, Fossati G, Paganin M, Michielotto B, De Paoli A, Basso G, Amadori A, te Kronnie G, Indraccolo S.

Cell Death Dis. 2016 Jan 14;6:e2047. doi: 10.1038/cddis.2015.394.

7.

Reduced SNAP-25 increases PSD-95 mobility and impairs spine morphogenesis.

Fossati G, Morini R, Corradini I, Antonucci F, Trepte P, Edry E, Sharma V, Papale A, Pozzi D, Defilippi P, Meier JC, Brambilla R, Turco E, Rosenblum K, Wanker EE, Ziv NE, Menna E, Matteoli M.

Cell Death Differ. 2015 Sep;22(9):1425-36. doi: 10.1038/cdd.2014.227. Epub 2015 Feb 13.

8.

Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.

Mensah AA, Kwee I, Gaudio E, Rinaldi A, Ponzoni M, Cascione L, Fossati G, Stathis A, Zucca E, Caprini G, Bertoni F.

Oncotarget. 2015 Mar 10;6(7):5059-71.

9.

Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.

Cleophas MC, Crişan TO, Lemmers H, Toenhake-Dijkstra H, Fossati G, Jansen TL, Dinarello CA, Netea MG, Joosten LA.

Ann Rheum Dis. 2016 Mar;75(3):593-600. doi: 10.1136/annrheumdis-2014-206258. Epub 2015 Jan 14.

PMID:
25589513
10.

Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.

Li S, Fossati G, Marchetti C, Modena D, Pozzi P, Reznikov LL, Moras ML, Azam T, Abbate A, Mascagni P, Dinarello CA.

J Biol Chem. 2015 Jan 23;290(4):2368-78. doi: 10.1074/jbc.M114.618454. Epub 2014 Dec 1.

11.

Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study.

Ronzoni L, Sonzogni L, Fossati G, Modena D, Trombetta E, Porretti L, Cappellini MD.

Br J Haematol. 2014 Jun;165(5):714-21. doi: 10.1111/bjh.12814. Epub 2014 Mar 7.

PMID:
24606390
12.

Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection.

Christensen DP, Gysemans C, Lundh M, Dahllöf MS, Noesgaard D, Schmidt SF, Mandrup S, Birkbak N, Workman CT, Piemonti L, Blaabjerg L, Monzani V, Fossati G, Mascagni P, Paraskevas S, Aikin RA, Billestrup N, Grunnet LG, Dinarello CA, Mathieu C, Mandrup-Poulsen T.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1055-9. doi: 10.1073/pnas.1320850111. Epub 2014 Jan 6.

13.

Reduced SNAP-25 alters short-term plasticity at developing glutamatergic synapses.

Antonucci F, Corradini I, Morini R, Fossati G, Menna E, Pozzi D, Pacioni S, Verderio C, Bacci A, Matteoli M.

EMBO Rep. 2013 Jul;14(7):645-51. doi: 10.1038/embor.2013.75. Epub 2013 Jun 4.

14.

Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activity.

Menna E, Zambetti S, Morini R, Donzelli A, Disanza A, Calvigioni D, Braida D, Nicolini C, Orlando M, Fossati G, Cristina Regondi M, Pattini L, Frassoni C, Francolini M, Scita G, Sala M, Fahnestock M, Matteoli M.

EMBO J. 2013 Jun 12;32(12):1730-44. doi: 10.1038/emboj.2013.107. Epub 2013 May 17.

15.

From filopodia to synapses: the role of actin-capping and anti-capping proteins.

Menna E, Fossati G, Scita G, Matteoli M.

Eur J Neurosci. 2011 Nov;34(10):1655-62. doi: 10.1111/j.1460-9568.2011.07897.x. Review.

16.

Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Dinarello CA, Fossati G, Mascagni P.

Mol Med. 2011 May-Jun;17(5-6):333-52. doi: 10.2119/molmed.2011.00116. Epub 2011 May 5.

17.

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, Dinarello CA.

Mol Med. 2011 May-Jun;17(5-6):353-62. doi: 10.2119/molmed.2011.00020. Epub 2011 Feb 22.

18.

The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.

Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G, Mascagni P, Dinarello CA.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):1-9. doi: 10.1097/QAI.0b013e3181d3dca3.

19.

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P, Rambaldi A, Neri A, Introna M, Lombardi L, Golay J.

Haematologica. 2010 Feb;95(2):260-9. doi: 10.3324/haematol.2009.012088. Epub 2009 Aug 27.

20.

Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo.

Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, Fossati G, Moroni F, Chiarugi A.

Neurobiol Dis. 2009 Nov;36(2):269-79. doi: 10.1016/j.nbd.2009.07.019. Epub 2009 Jul 25.

PMID:
19635561

Supplemental Content

Loading ...
Support Center